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Objective: To measure patterns of clinical activity at colposcopy before and after vaccinated women entered the Scottish Cervical Screening Programme (SCSP).

Design: Population-based observational study using nationally collected data. 

Setting: Scottish colposcopy clinics.

Sample: All women with a date of birth on or after 1 January 1985 who attended colposcopy in Scotland between 2008-2014.

Methods: Routinely collected data from the Scottish National Colposcopy Clinical Information Audit System (NCCIAS) was extracted, including: referral criteria, referral cervical cytology, colposcopic findings, clinical procedures and histology results. Analysis was restricted to those referred to colposcopy at age 20 or 21 years.

Main outcome measures: Referral criteria, positive predictive value of colposcopy, default rates and rates of cervical biopsies and treatments.

Results: 7372 women referred for colposcopy at age 20/ 21 years were identified. There was a  downward trend in the proportion of those referred with abnormal cytology (2008/9: 91.0%, 2013/14: 90.3%, linear trend p value = 0.03). Women were less likely to have diagnostic or therapeutic interventions. The proportion with no biopsy (2008/9: 19.5%, 2013/14: 26.9%, linear trend p value < 0.0001) and no treatment (2008/9: 74.9%, 2013/14: 91.8%, linear trend p value < 0.0001) increased over the period of observation. 

Conclusions: A reduction in clinical activity related to abnormal screening referrals is likely to be associated with the HPV catch-up immunisation programme. Referral criteria and service provision of colposcopy needs to be planned carefully taking account of the increasing number of HPV- immunised women that will be entering cervical screening programmes worldwide.
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Tweetable Abstract: Colposcopy referral criteria and service planning need attention following HPV immunisation programme 

Introduction
Immunisation against the two human papillomavirus (HPV) genotypes, HPV 16 and 18, found in 70% of cervical cancers, promises a substantial reduction in high grade cervical intra-epithelial neoplasia (CIN) by 67% and cervical cancers by 70% 1.  These predictions assume that high vaccine uptake in the population is high and any maintenance of existing cervical screening programme is maintained.  A significant decline in genital warts, from 11.5% in 2007 to 0.85% in 2011, was seen in young Australian women following implementation of an immunisation programme using the quadrivalent vaccine2.   Data from Queensland, Australia2 indicated a significant decrease in high grade cervical cytology in women vaccinated before the age of 18 years.  The realisation of these such benefits implies infers  reducedless demand for related clinical services.

In the UK, routine HPV vaccination of girls aged 12-13 as part ofin the school immunisation programme started in 2008, together with a 3 year ‘catch-up’ programme’ for girls up to 18 years. This was introduced designed to expand the immunised cohort and reduce the lag time to achieving the benefits of from vaccination 3.  Uptake rates for 3 doses in Scotland are high; almost 90% of girls routinely immunised eligible forin the school programme and 65.5% in catch-up  received all three doses 3,4  with equitable uptake by deprivation score 5. 
.  In Scotland, 65.5% of girls in the catch-up programme received 3 doses although uptake was highest in those in school compared with school leavers4.  

At the time of this study, women became eligible for cervical screening in Scotland at age 20. Women offered immunisation in the catch up programme therefore became eligible for screening in 2010.Women offered the vaccine as part ofin catch-up became eligible for cervical screening in 2010 at age 20 in Scotland. Existing Scottish data from Scotland has shown that a 3-dose programme using the bivalent vaccine in from the catch-up cohort was associated withshows a reducedtion in the prevalence of HPV16/18 in women aged 20 from (29.8% to 13.6%)7 and also .  Reduced prevalence of other high risk HPV types, HPV 31, 33 and 45, was reported suggesting cross protection7.  A significant reduction in CIN 1 (RR 0.71), CIN 2 (RR 0.5) and CIN 3 (RR 0.45) was observed in fully vaccinated women compared with unvaccinated women8.  Furthermore, there is a reduction of HPV16/18 in unvaccinated 20 year olds whose peers were vaccinated.7.  While this is undoubtedly encouraging, the reduced prevalence of HPV infection and CIN prevalence has clear implications for cervical screening.  We recently demonstrated that the predictive values of abnormal cytology for CIN have reduced in immunised women, with a concomitant significant increase in the referral value (the number of women required to be referred to colposcopy on the basis of abnormal cytology to detect a case of CIN2+) by 38%9. 

To inform colposcopy service provision as part of a national screening programme, we measured changes in the referral and colposcopy activity patterns, colposcopy performance, CIN detection and clinical activity at a population level using routinely collected clinical data in a cohort of women offered catch up HPV vaccination as part ofin a national catch up campaign.  Specifically, weWe aimed to monitor the pattern of new referrals to colposcopy;  rates of diagnostic and therapeutic interventions at colposcopy; the positive predictive value (PPV)), sensitivity and specificity of colposcopic impression for high grade CIN; the negative biopsy rate (proportion of cervical biopsies with no CIN detected) among those undergoing interventions at colposcopy and the rate of default to colposcopy appointments, among groups of young women who hadwith increasing rates of HPV vaccination over a period of observation.

Methods
Up to 6/6/2016, the eligible population for the Scottish Cervical Screening programme has been women aged 20-60 years with 3 yearly screening using liquid based cytology. Referral to colposcopy is based on a single high grade result or repeated low grade or borderline nuclear abnormalities. HPV testing is not used for screening or triage of low grade disease. We conducted an observational study using national data. Up to 6/6/2016, the eligible population for the Scottish Cervical Screening programme has beenwas women aged 20-60 years with 3 yearly screening using liquid based cytology. Referral to colposcopy is based on a single high grade result or repeated low grade or borderline nuclear abnormalities. HPV testing is not used for screening or triage of low grade disease. Colposcopy data are collected routinely for all women referred to colposcopy in NHS Scotland via the National Colposcopy Clinical Information and Audit System (NCCIAS),.  This is a web-based system which links to the Scottish Cervical Call Recall System (SCCRS), the national information technology system for the management of the cervical screening programme.  NCCIAS  includes women referred to colposcopy with either abnormal cytology via SCCRSfrom the screening programme or on clinical grounds (with no cytology or normal cytology).  Information is episode based and includes patient demographics, appointment details (including attendance/default), clinical data including indication for referral (e.g. abnormal cytology, clinical signs and symptoms), colposcopy assessment and findings, biopsy results, cytology results, treatment methods and the follow-up management plan. Data entry and quality checks are conducted locally and the data are routinely used to produce clinic correspondence to referring  practitioners and to women, to monitor colposcopy performance for British Society for Colposcopy and Cervical Pathology (BSCCP) accreditation10  and to bench mark key performance indicators as part of quality assurance of Scottish colposcopy services. 

We obtained a NCCIAS data extract from NHS Scotland Information and Statistics Division (ISD), which contained the records for all women whose date of birth was on or after 1 January 1985 and who were referred to colposcopy in Scotland 2008-2014 inclusive. Data was anonymised by ISD. The analysis was restricted to those referred for colposcopy at age 20 or 21 to increase the likelihood of women being seen at colposcopy following their initial cervical screen. The performance of colposcopy was assessed by calculating the sensitivity, specificity, PPV and negative predictive value (NPV) with the definitive histology result. Women with normal colposcopy were assumed to have no disease at the time of examination. Performance was calculated at two different cut-offs of disease outcome: for CIN2+ and for any grade of CIN.  Evidence of a linear change in performance indicators and proportions over allthe  time points was assessed by logistic regression. As a number of models were run, an with adjustment for multiple testings, using the Benjamini-Hochberg false discovery rate procedure  a Bonferroni correction was applied, separately to each table, to the traditionally used significance cut-off point of alpha=0.05. A total of 52 trend tests was conducted, therefore this gavegives the new significant levelcut-point alpha = 0.05/52 = 0.00096.  This leads to stricter criteria for declaring statistically significant results and the clinical significance of all results was also considered.. All statistical analysis was conducted in R (R Core Team (2015)), version 3.1.

Approvals
This study was sponsored by the University of Aberdeen. It received REC approval from North of Scotland REC (11/NS/0022) on 9th September 2011. Approvals were also obtained from the Scottish Colposcopy QA Group and the Caldicott guardians in each Scottish NHS Health Board.

Results
Pattern of referrals 
During 2008-2014, there were a total of 31,634 new episodes recorded for women referred to colposcopy with 7372 unique women referred for colposcopy at age 20 or 21 (age 20: 3337, age 21: 4035). The number of referrals generally decreased over the period of observation (See Table 1). There was a slight non-significant downward trend in the proportion referred with an abnormal screening smear (2008/9; 1294 (91.0%), 2013/14; 758 (90.3%); linear trend p value = 0.03).  Whilst the absolute numbers declined, the proportion with borderline nuclear abnormalities (BNA) and low grade dyskaryosis increased significantly.  This was matched by with a corresponding significant reduction in the proportion of women referred with high-grade dyskaryosis and any grade of dyskaryosis (2008/9; 41.2%, 2013/14; 30.7%; linear trend p value <=0.01).   The number of women with high grade dyskaryosis had more than halved from 533 in 2008/9 to 233 in 2013/14, though the 2008/09 figure is potentially an outlier.   Women are also referred to colposcopy out with the screening programme for clinical reasons.  For these women, there was an increasing trende in the proportion referred to colposcopy with a clinically suspicious cervix (2008/9; 1.6%, 2013/14; 3.1%, linear trend (p = 0.02) but there was no change in the presence of any specific gynaecological symptom (e.g. intermenstrual bleeding (IMB) or post-coital bleeding (PCB) (See Table 1). 

Rates of diagnostic and therapeutic interventions 
Table 2 shows data from 7013 individual women aged 20-21who had a colposcopy examination during 2008-2014. The full data set is available in Table S1.  The adequacy of colposcopy is assessed by the type of transformation zone (TZ) identified using the International Federation of Colposcopy and Cervical Pathology (IFCPC) terminology 201112. There was an increasing trend in the proportions of women with a type 2 TZ.  Women with a colposcopically normal cervix, assessed  by the  absence of abnormal colposcopic features (no acetowhite; no capillary vessel patterns (mosaic and/or punctation) or no abnormal vessels), increased (2008/9: 138 (10.3%), 2013/14; 112 (14.0%); linear trend p value =0.002< 0.01) while the proportion with a colposcopic impression of high-grade CIN decreased (2008/9; 458 (34.1%), 2013/14; 217 (27.0%); linear trend p value < 0.01=0.004).  We note that the major change takes place in 2012/13.  Over the period of observation, the proportion of women having no clinical interventions (biopsy or treatment) increased (2008/9; 19.5%, 2013/14; 26.9%, linear trend p value <0.0001). The proportion having diagnostic punch biopsy/biopsies or treatment (most commonly loop excision or cold coagulation (also known as thermocoagulation)) decreased with the number of therapeutic procedures falling from 318 in 2008/9 to 62 in 2013/14. However, we observed an unexpected increase in the proportion of women having a cytology test performed at colposcopy (2008/9; 4.2%, 2013/14; 5.6%, linear trend p value = 0.02).

Performance of colposcopy: PPV, sensitivity and specificity for high grade CIN on histology 
The number and proportion of women with high grade disease (CIN2+) confirmed on histology decreased significantly (2008/9; 527 (39.2%), 2013/14; 207 (25.8%), linear trend p value <0.0001). Table 3 shows the performance of colposcopy to predict or exclude CIN. The PPV of colposcopy for CIN2 or worse (CIN2+) on biopsy decreased significantly from 79% in 2008/9 to 67% in 2013/14 (linear trend p value < 0.001=0.0002), though with the main change associated with 2013/14. The PPV of colposcopy for any grade of CIN or more (CIN+) on biopsy decreased from was relatively unchanged,  84% in 2008/9 andto 80% in 2013/14 but this was not significant (linear trend p value = 0.32). We did not find any significant change in sensitivity and specificity of colposcopy to predict CIN2+ on biopsy over the period assessed, except a small reduction in the specificity of colposcopy to predict CIN2+ (2008/9; 84%, 2013/14; 80%; linear trend p value = 0.02).

Negative biopsy rate 
During 2008-2014, 5535 women aged 20-21 had a biopsy performed at colposcopy visit. The negative biopsy rate, calculated as the proportion of women who had a biopsy taken but the histology reported as normal or no CIN, showed no significant change over the period of observation (2008/9; 23.8%, 2009/10; 28.0 %, 2010/11;25.0%, 2011/12; 25.8 %, 2012/13; 25.2% and 2013/14;27.8% linear trend p value = 0.4).

Default from first attendance at colposcopy rate




The results from this  observational study ofecological population-based data study indicate a reduction in the absolute numbers of young women referred to colposcopy from the catch-up cohort offered HPV immunisationimmunisationprogrammein the catch-up programme. The timeframe of the data collection and the size of the effect suggests that this is likely to be associated with HPV vaccination offered as the catch-up programme. NCCIAS is a valuable resource in Scotland providing national data on colposcopy activity and performance for quality management and service delivery.  We have been able to observe changes in colposcopy practice following immunisation.  Previous studiespublications have confirmed the reduction in HPV vaccine type genotypes and the performance of cytology as a consequence of immuniationimmunisation 5-9 , whileand have flagginged up the need to review the screening pathway.  This is the first population-based studyaper to demonstrate a reductedion in colposcopy activity and the performance of colposcopy based on population wide data. We have also confirmed the reported changes in colposcopy performance linked to vaccine status 11.  The majority of HPV vaccine impact studies have focused on the effect on circulating HPV types 6,7, 12, 13 and screening cytology 2, 8,9,12.  The sentinel surveillance system in the United States reported a 26% reduction in HPV16/18 associated CIN2+ from five catchment areas, following HPV vaccination14  but did not discuss the impact on service provision..  





Although the numbers are small, the proportion of women referred to colposcopy with gynaecological signs, rather than an abnormal screening test, has increased.  It was not possible to measure the service impact from the initial HPV vaccine trials as these whichwere not population based 13, 14, 15. The majority ofMost other published HPV vaccine  impact studies have focused on the effect on HPV surveillancecirculating HPV types 6,7, 12, 13 and screening cytology 2, 8,9,12.  The sentinel surveillance system in the United States did reported a 26% reduction inreduced HPV16/18 associated CIN2+ from five catchment areas, from 54 to 28% following HPV vaccination14  but did not discuss the impact on service provision is missing.  

Gynaecology services allocate patients with ‘red flag’ symptoms of cervical cancer to different services which may include colposcopy, general gynaecology, gynaecology/ oncology or sexual health. We speculate that theTheis increase in symptomatic women referred with symptoms iscould be due to a change in referral directed byresult from the colposcopy services who may beresults frommay be the result of optimising spare colposcopy clinic capacity by accepting referrals which could otherwise be seen at other gynaecology clinics,,  and relieving pressure on other gynaecological services rather than being driven by increased suspicion of cervical cancer in this low risk cohort.  Gynaecology services may allocate patients with ‘red flag’ symptoms of cervical cancer to different services which may include colposcopy, general gynaecology, gynaecology oncology or sexual health. TIt could be that these referrals are possibly being routed through colposcopy if there are available appointments or disparities in waiting times. This would maintain skills and the use of colposcopy clinic capacity, time and staffing, and may relievinge pressures on other gynaecology services.

A further effect on managing the colposcopy demand will be the time available for either the duration or number of appointments.  Women who are scheduled or expected to have treatment at colposcopy are allocated a longer appointment time than for diagnostic-only colposcopy. Thus, fewer treatment slots liberates proportionately more clinic time. The unanticipated increase in cytology sampling at colposcopy could have two explanations: either a relative increase in the number of women referred with symptoms or signs who are due to befor screeninged; or colposcopists managing their own clinical uncertainty in low risk young women by repeating cytology.  This is national data and it does not suggest a local problem.  The practice of repeating cytology at colposcopyThihe latters is not evidence- based and should be addressed at clinic and national guideline level to avoid unnecessary procedures which are unlikely to contribute effectively to further patient management.  Like many other countries, colposcopy services in Scotland have developed or been commissioned locally, although a few countries such as the Republic of Ireland contract colposcopy services and capacity as part of their national screening programme.  National direction from the screening programme may be necessary to address the issues of referral criteria, capacity and clinical management highlighted by our results.

For women referred with an abnormal cytology, there has been a significant declining trend in all grades of dyskaryosis within screening programmes associated with vaccination 10, 19,20.  Our data corroborates that from Australia with reduced low and high grade cytology in young women since the catch- up HPV immunisation programme16. We previously reported an increase in normal cytology and reduction in all grades of abnormal cytology including borderline changes10 in the screened population.  A similar reduction in all grades of CIN to that reported here, with less than half the number of cases of CIN2+ in 2013-14 compared with 2008-2009, was associated withobserved as a consequence of vaccination in Scotland9, supporting our interpretation that the changes observed at colposcopy relate to HPV vaccination. 

It is importantly, wto note that eWe are reporting on women who meet the criteria for colposcopy referral (which includes three borderline changes or two low grade dyskaryosispersistent low grade disease) (HPV triage is not used in Scotland) compared with single abnormalities reported in the screened population89.  Prior toBefore vaccination, the risk of associated CIN with persistent BNA or low grade changes was sufficient to warrant investigation at colposcopy.  In ourthis present analysis, we identified an increaseing proportion ofin women referred to colposcopy with no identifiable CIN.  It is unsurprising that fewer colposcopic features associated withof CIN were recorded, fewer biopsies taken and fewer treatments performed.  Although not previously reported, this effect could haveThis corroboratesis consistent with been anticipated from our previous report of theobservation that the increased referral value of cytology increased in immunised women9 and highlights strengthensstrengthening the needour callthe need to review referral criteria based to reflect the reduced on risk of underlying CIN.  National direction from the screening programme may be necessary to address the issues of referral criteria, capacity and clinical management highlighted by our results..  National direction from the screening programme may be necessary to facilitate this,

Strengths and limitations
Our study uses nationwide colposcopy data on all women referred to colposcopy in NHS Scotland- the organised nature of the screening programme behovesadvocates that national guidelines are followed, mitigating to an extent the influence of individualised practice.  Women with abnormal cytology which meet the criteria for referral have a ‘direct referral’ made from the cytology laboratory via the SCCRS system to their local colposcopy service.  Alternatively clinical referrals on the basis of gynaecological signs or symptoms can be made directly and these are also recorded with details of the indication.  LColposcopy lead colposcopistslinicians are responsible for data entry and quality management of data within NCCIAS15.  The production of standard letters using these data also supports quality assurance. 

This is an ecological study but although and there is no linkage from NCCIAS to the national immunisation record.  However, the magnitude of the change in activity at colposcopy, the temporal relationship withto implementation of immunisation and the effect reported from screening data in Scotland 7,8, 9  indicates that these effects are likely to result from theattributable to  HPV immunisation programme.  Although completion of 3 doses has been reported at over 65% in the catch-up cohort, this was highest in those girls vaccinated in school (80% uptake) and lower (30% uptake) in those who had left school5.  Our data comes from the catch-up programme and the maximum effect, when women vaccinated in the school programme attend screening, of vaccination is yet to be seen when women vaccinated in the school programme at earlier ages (with less likelihood of prior exposure to HPV) and with higher vaccine uptake rates attendstart screening. 

 Rates of CIN detection and colposcopy activity will also be affected by the uptake of cervical screening.  There have been conflicting reports on screening attendance in vaccinated women 22,23, 24,. This is against a background of low screening attendance in this age-group. Like other countries with population based screening, Scotland has reported decreasing uptake rates with an overall uptake, across all ages, of 70.7% in 2013-14. However, uptake is considerably lower in young women with only 50.9% women aged 20-24 years having attended for a smear in the last 3.5 years 25.  We have previously demonstrated an increase in uptake of screening in women vaccinated in the catch-up programme22.  

Whilst uptake of HPV vaccine worldwide varies in relation to its cost, delivery strategy, deprivation, and age of consent, the most important factor in promoting uptake appears to be providing vaccination in a school based programme 26-28. The Australian and Swedish linkage data studies have highlighted the impact of social deprivation on both vaccination and screening uptake 16, 24.  However, Scottish data indicates a minimal gradient in uptake of vaccine in relation to deprivation scores and higher attendance for screening in those women from lower social economic groups who have been vaccinated compared with those who are unvaccinated22.  Our data raises the possibility that the lower rate of default from colposcopy over the time period observed may be attributed to higher attendance in vaccinated women compared with unvaccinated. This could be related to a number of factors independent to HPV vaccination such as targeted interventions to reduce default and public education at vaccination and screening.  Socio-economic status is an additional confounder as attendance for initial cervical screening is higher in women with lower levels of deprivation and these women are less likely to have cervical disease29.

The results from this observational studyOur results could be affected by a number of possible biases. Following the death of a media celebrity in the UK in 2009, there was an increase in the uptake of screening and detection of CIN and cervical cancer in particularly in younger women which was not subsequently sustained 17.  This would have increasedaccount for the number of abnormalities detected in 2009 in compared withison to previous or subsequent years. There was national standardisation of referral criteria for low grade dyskaryosis from a single to two consecutive low-grade cytology tests in 2012, bringing two of the larger health boards into alignment with the practice of the remaining 12 Scottish boards. In 2013, cytology terminology changed so a previous ‘BNA with koilocytes’ were classified as low grade dyskaryosis.  This will have altered the reporting profile but would not explain the increase in BNA reports.  We have previously reported that the number of young women participating in screening  has  not decreased in recent years so fewer cases does not reflect lower attendance9. The HPV vaccination campaign in schools and primary care prompted dissemination of information on HPV and immunisation for girls and parents including in the national media.  The effect of these factors cannot be measured in this study.

Interpretation
As larger proportions of routinely vaccinated women join the screening programme, the impact of vaccination on colposcopy activity and performance may be even greater than described in the present study.The effect of vaccination on colposcopy activity and cervical disease should precipitateincrease as a larger proportion of routinely vaccinated women enter ingthe screening programme. These women are less likely to have been exposed to HPV prior to receiving and completing the vaccine course and will have mounted an optimal antibody response at a younger age than those in the catch-up programme reported here. Our surveillance systems continue to measure the effect of routine vaccination of 12-13 year olds who started to attend for screening in 2015. The change to the age range and frequency for screening in Scotland implemented in June 2016, which raises the entry age to 25 years in harmonisation with the rest of the UK 30 will limit the measurable cohort size available until 2020.

The demand for colposcopy services, and hence the capacity to manage screening, will be is influenced by a number of factors including the target screening population, the screening test used, and the referral criteria. Other influences include  vaccine uptake rates, the type of vaccine and the dosing schedule as well the health- seeking behaviours of the population.  Demand for cColposcopy requirements of the screening programme will fall and Sspare capacity at colposcopy carries a cost to the health service.; Uusing tcolposcopy services to manage other general gynaecological conditions may not be the most efficient use of a specialist resource. Equally, but may allow quality assurance and maintenance of colposcopy skills requires colposcopists to see sufficient numbers of women with CIN to maintain their pattern recognition and operative skills, and assure quality of the service 10. In the UK, the key performance indicator is the positive predictive value (PPV) of colposcopy with the lowest acceptable PPV of colposcopy for high grade CIN set at 65% 18. O PPV is a function of the prevalence of the disease in the screened population Although ooOur data indicates that the PPV of colposcopy in women aged 20-21 years has fallen and is now, it remains just above this bench mark.  iIndicating that the cut-off for referral to colposcopy needs review.   However, the The trends observed indicates that without change,FFurthermore, this threshold may well be breached with an increasingly vaccinated population.  PPV is a function of the prevalence of the disease in the screened population and the cut-off for referral to colposcopy needs review for this emerging cohort of women to ensure a level of risk of CIN2+ that justifies further intervention.  We do not yet have data to support alternative screening strategies based on vaccination status.  This would require robust linked data on vaccination status to implement safely.  Such an approach may not be valid with high vaccine uptake as there is evidence of some protection of unvaccinated women in our population7,8.  

In Scotland, the peak prevalence of CIN3 is found in 25-29 year old age band19 which accounts for almost a third of all cases per annum. The proportion of cases of CIN3 diagnosed in 20-24 year age band represents the 2nd highest proportion at 21-24%. As the prevalence of CIN3 continues to fall over the next 5 years in both age groups, we need to ensure that any rationalisation of colposcopy services considers the need to maintain the necessary expertise to diagnose and treat women as part of cervical cancer prevention.  Whilst there are a number of new technologies which aim to be an adjuvant to traditional colposcopy20.21, their performance also relies on the prevalence of CIN in the referral population. 

Other potential changes to the screening programme and prevalence of CIN such as the introduction of primary HPV screening or other alternatives to cytology will impact on referral to colposcopy.  It is inevitable that the anticipated potential of vaccination to reduce cervical cancer in the future will reduce secondary prevention activity; service planning needs to address this foreseeable change.  We have reported less clinical activity.  Those planning future services need to consider ifShould colposcopy training and staffing should be allowed to undergo attrition, or if do we thinkshould the existing clinical capacity should be used for other patient groups who would benefit from the same clinical expertise?. Whilst colposcopy skills are transferrable to intra-epithelial disease at other lower genital tract sites, this will require additional training or upskilling for staff who currently only deal with cervical disease.  Alternatively, it may not be an efficient use of health resources to continue to offer colposcopy examination to women who do not require the same level of intervention. such as women with gynaecology symptoms from hormonal contraception or infection.

Conclusion
A reduction in colposcopy workload , clinical activity  and associated clinical activity is likely to be related to the HPV immunisation.   in addition to initial evidence of reduced predictive value fir CIN2+ programme. The implications forReview of referral selection and service provision (including referral criteria) which takes into account the increasing number of vaccinated women who will enter screening review as high vaccine uptake in school based programmes will have a greater impact on service provision and deliveryis required to ensure the continued delivery  of an effective colposcopy service.
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